当前位置:首页 - 行情中心 - 瑞普生物(300119) - 财务分析 - 现金流量表

瑞普生物

(300119)

  

流通市值:58.50亿  总市值:80.31亿
流通股本:3.39亿   总股本:4.65亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,621,456,169.29748,563,081.113,420,890,570.732,513,837,702.62
  收到的税费返还4,660,283.371,794,143.565,003,379.634,901,396.2
  收到其他与经营活动有关的现金56,093,528.4711,244,87377,931,842.16499,351,509.18
  经营活动现金流入小计1,682,209,981.13761,602,097.673,503,825,792.523,018,090,608
  购买商品、接受劳务支付的现金901,529,380.36461,322,813.41,875,217,866.961,412,739,086.4
  支付给职工以及为职工支付的现金257,529,799.38139,289,062.32511,182,431.06394,426,840.27
  支付的各项税费118,735,742.6551,262,720.06164,256,998.13121,765,847.09
  支付其他与经营活动有关的现金210,770,965.3998,377,975.36655,634,877.97883,278,529.02
  经营活动现金流出小计1,488,565,887.78750,252,571.143,206,292,174.122,812,210,302.78
  经营活动产生的现金流量净额193,644,093.3511,349,526.53297,533,618.4205,880,305.22
二、投资活动产生的现金流量:
  收回投资收到的现金913,132,056485,712,4832,739,125,076.162,086,276,451.16
  取得投资收益收到的现金10,160,206.652,646,592.7582,686,982.4576,012,964.06
  处置固定资产、无形资产和其他长期资产收回的现金净额85,542.4761,043.66276,375.45185,589.8
  处置子公司及其他营业单位收到的现金净额--92,457,782.9892,457,781.98
  收到的其他与投资活动有关的现金--616,205.4934,902.98
  投资活动现金流入小计923,377,805.12488,420,119.412,915,162,422.532,254,967,689.98
  购建固定资产、无形资产和其他长期资产支付的现金97,190,768.7349,547,182.27176,103,686.05112,457,681.97
  投资支付的现金1,038,659,624592,099,6242,466,284,3061,911,673,000
  取得子公司及其他营业单位支付的现金5,100,000-170,550,000170,550,000
  投资活动现金流出小计1,140,950,392.73641,646,806.272,812,937,992.052,194,680,681.97
  投资活动产生的现金流量净额-217,572,587.61-153,226,686.86102,224,430.4860,287,008.01
三、筹资活动产生的现金流量:
  吸收投资收到的现金7,018,000980,0001,130,0006,600,000
  其中:子公司吸收少数股东投资收到的现金7,018,000980,0001,130,0006,600,000
  取得借款收到的现金825,168,155.57173,517,061.651,186,430,465.2876,364,265.4
  收到其他与筹资活动有关的现金1,000,0001,001,0007,341,497.816,361,779.39
  筹资活动现金流入小计833,186,155.57175,498,061.651,194,901,963.01889,326,044.79
  偿还债务支付的现金669,538,818.46106,457,577.61,059,436,851.2776,378,297.4
  分配股利、利润或偿付利息支付的现金215,167,779.229,226,844.17224,835,731.46215,210,742.11
  其中:子公司支付给少数股东的股利、利润18,171,690.321,731,090.6557,339,657.5854,829,640.02
  支付其他与筹资活动有关的现金22,899,483.2741,212.69161,095,521.63153,492,385.83
  筹资活动现金流出小计907,606,080.88116,425,634.461,445,368,104.291,145,081,425.34
  筹资活动产生的现金流量净额-74,419,925.3159,072,427.19-250,466,141.28-255,755,380.55
四、汇率变动对现金及现金等价物的影响-1,393,037.36-517,499.31-1,817.85196,030.85
五、现金及现金等价物净增加额-99,741,456.93-83,322,232.45149,290,089.7510,607,963.53
  加:期初现金及现金等价物余额625,515,953.29625,515,953.29476,225,863.54476,225,863.54
  期末现金及现金等价物余额525,774,496.36542,193,720.84625,515,953.29486,833,827.07
补充资料:
  净利润221,915,239.8-434,469,249.03-
  资产减值准备17,759,374.71-41,434,927.25-
  固定资产和投资性房地产折旧78,369,075.71-161,951,090.15-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧78,369,075.71-161,951,090.15-
  无形资产摊销26,185,096.98-50,202,526.96-
  长期待摊费用摊销330,446.57-520,261.69-
  处置固定资产、无形资产和其他长期资产的损失-2,822.84--3,819,392.15-
  固定资产报废损失60,239.52-1,295,915.14-
  公允价值变动损失-10,086,942.92--75,831,147.54-
  财务费用16,058,154.9-35,416,250.71-
  投资损失-6,666,382.23--34,221,849.5-
  递延所得税-3,068,164.29--17,793,813.96-
  其中:递延所得税资产减少-1,037,312.41--9,999,075.03-
    递延所得税负债增加-2,030,851.88--7,794,738.93-
  存货的减少7,102,042.24--9,389,028.39-
  经营性应收项目的减少-276,278,300.99-1,758,171.48-
  经营性应付项目的增加116,394,970.97--301,818,372.86-
  其他1,592,455.02-1,900,143.11-
  现金的期末余额525,774,496.36-625,515,953.29-
  减:现金的期初余额625,515,953.29-476,225,863.54-
  现金及现金等价物的净增加额-99,741,456.93-149,290,089.75-
公告日期2026-08-262026-04-282026-03-312025-10-25
审计意见(境内)标准无保留意见
TOP↑